Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hCTMSCs for Long COVID Neurological Symptoms
NCT06156241Phase 1Not yet recruiting
- Start
- Jan 2024
- Primary completion
- Dec 2025
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of allogeneic human cord tissue-derived mesenchymal stromal cells in post acute COVID-19 syndrome (4 arms). Primary endpoint: Infusional Toxicity of the Cell Product at 24 hours. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
allogeneic human cord tissue-derived mesenchymal stromal cells
03
Conditions
post acute COVID-19 syndrome
Beyond the preview
Go deeper on NCT06156241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06156241.